Acute Decompensated Heart Failure+Atrial Fibrilation: Case Report
Keywords:
Acute Decompensated Heart Failure, Atrial Fibrilation, Pharmacology therapyAbstract
Heart Failure is a health issue with high mortality and morbidity rates in both developed and developing countries, such as Indonesia. The prevalence of heart failure in Asia is generally similar to that reported in Europe (1–3%), while in Indonesia, the prevalence is reported to be greater than 5%. Heart failure increases among geriatric patients, affecting 6% of those aged 60-79 years and up to 14% of those over 80 years old. Acute Decompensated Heart Failure (ADHF) is the progressive worsening of symptoms and clinical signs of heart failure in patients who have been previously diagnosed with the condition. The underlying mechanisms of clinical deterioration in patients include increased congestion and disease progression. ADHF and atrial fibrillation (AF) often occur together and can lead to hemodynamic instability and death. AF is the most common supraventricular dysrhythmia in patients with ADHF, with a prevalence of 25%-40%. The combination of ADHF and AF results in adverse clinical outcomes, including prolonged hospitalization and increased mortality. A 50-year-old woman complained of shortness of breath accompanied by palpitations that started 10 days before hospital admission and worsened in the last 2 days. The patient has a history of an enlarged heart for the past 3 years. A transthoracic echocardiogram revealed atrial fibrillation with a rapid ventricular rate (RV) of 90-130 beats per minute, left ventricular dilation (LVIDd 5.5 cm), decreased right ventricular systolic function (TAPSE 1.4 cm), left atrial dilation (LAVI 64.45 ml/m²), and right atrial dilation (RA major 5.8 cm). The electrocardiogram showed atrial fibrillation, abnormal ST & T waves, and prolonged ǪT interval.
References
Dávalos A, Alvarez-Sabín J, Castillo J, Díez-Tejedor E, Ferro J, Martínez-Vila E, et al. Citicoline in the treatment of acute ischaemic stroke: An international, randomised, multicentre, placebo-controlled study (ICTUS trial).Lancet. 2012;380(9839):349–57. http://dx.doi.org/10.1016/S0140-6736(12)60813-7
Dimarco JP. Atrial fibrillation and acute decompensated heart failure. American Heart Association. 2009;2(1):72–3.
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Vol. 145, Circulation. 2022. 895–1032 p.
Joshua D. Niforatos MD M, Michael R. Ehmann MD, MPH M, Kamna S. Balhara MD M, Jeremiah S. Hinson MD P, Lukas Ramcharran MD M, MLIS KL, et al. Management of atrial flutter and atrial fibrillation with rapid ventricular response in patients with acute decompensated heart failure: A systematic review. 2023;9.
Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D, et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Vol. 52, Stroke. 2021. 364–467 p.
Mach F, Colin Baigent, Alberico L. Catapano. 2019 ESC/EAS Guidelines for themanagement of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Society Cardiology. 2020;41(8–9):78.
PERKI. Pedoman Tatalaksana Gagal Jantung. Perhimpunan Dokter Spesialis Kardiovaskular Indonesia. 2023;115.
PERKI. Pedoman Tatalaksana Fibrilasi Atrium Non-valvular. Perhimpunan Dokter Spesialis Kardiovaskular Indonesia. 2019;54–5.
Theresa A. McDonagh. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Society of Cardiology; 2021. p. 128.